Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy
Year: 2016
Type: article
Abstract: The examination of antibody responses in human immunodeficiency virus (HIV)-1-infected individuals in the setting of antiretroviral treatment (ART) interruption can provide insight into the evolution of antibody responses during viral rebound. In this study, we assessed antibody responses in 20 subjects in AIDS Clinical Trials Group A5187, wherein subjects were treated with antiretroviral therapy during acute/early HIV-1 infection, underwent analytic treatment interruption, and subsequently demonstrated viral rebound. Our data suggest that early initiation of ART arrests the maturation of HIV-1-specific antibody responses, preventing epitope diversification of antibody binding and the development of functional neutralizing capacity. Antibody responses do not appear permanently blunted, however, because viral rebound triggered the resumption of antibody maturation in our study. We also found that antibody responses measured by these assays did not predict imminent viral rebound. These data have important implications for the HIV-1 vaccine and eradication fields.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofw100
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,053
Awards: Impact of HIV Envelope Conformation on Immunogenicity, Diversity of Immune Responses Elicited by HIV Vaccines, Consortium for AIDS Vaccine Research in Nonhuman Primates, Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine, Novel Ad/MVA and Ad/Protein HIV-1 Vaccines, G9000129761, G9000167652, G9000192307, G9000300565, G9000336039, Harvard University Center for AIDS Research
OpenAlex ID: W2430425988